These collective observations suggest that PI3K/Akt/mTOR pathway inhibition would be suited to manage the advanced proliferative stages of diabetic retinopathy where hypoxia-driven vasoproliferative mechanisms predominate in contributing to the vasculopathy. The gene discussed is AKT1; the disease is vascular disorder.